NASDAQ : BLSM
BlossomHill Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 15.21 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 483.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 399.38M |
| Enterprise Value | 327.37M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 31.78M |
| Shares Outstanding | 31.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +5.18% |
| Owned by Insiders (%) | 7.89% |
| Owned by Institutions (%) | 7.44% |
| Float | 17.74M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.42 |
| Quick Ratio | 5.12 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -80.79% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.18M |
| Employee Count | 69 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 18.90 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 34.26 |
| Average Volume (20 Days) | 139,302 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 484,963 |
| Short Previous Month | 473,807 |
| Short % of Shares Out | 1.53% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 2.12 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -85.24M |
| Pretax Income | -81.60M |
| Net Income | -81.60M |
| EBITDA | -84.74M |
| EBIT | -85.24M |
| Earnings Per Share (EPS) | -$31.83 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 95.38M |
| Total Debt | 23.37M |
| Net Cash | 72.01M |
| Net Cash Per Share | $2.27 |
| Equity (Book Value) | 82.04M |
| Book Value Per Share | -63.15 |
| Working Capital | 82.35M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -70.98M |
| Capital Expenditures | -83,000 |
| Depreciation & Amortization | 504,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -71.06M |
| FCF Per Share | -$2.24 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -253.30% |
| FCF Yield | -17.96% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.40 |
| Price Target Difference | 181.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |